Endogenous Retrovirus Group V Member 1 (ERVV-1): Market Intelligence, Tumor-Associated Antigen Validation, and High-Purity Reagents for Immunotherapy Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for ERVV-1 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | ERVV-1 ECD-Fc Fusion Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 Expressed (Native Glycosylation). Theoretical MW confirmed. |
View ERVV-1 Products |
| Gene Delivery | ERVV-1 Lentivirus Premade Particles Full-length ORF for stable cell line construction. High titer (>10^8 TU/mL). |
View ERVV-1 Products |
| Benchmark Ab | Anti-ERVV-1 Reference Antibody Recombinant positive control for binding assay validation. Sequence Verified. |
View ERVV-1 Products |
| Validator | ERVV-1 siRNA Set For knockdown specificity verification. Sequence-confirmed targeting. |
View ERVV-1 Products |
| Related Target A | ERVV-2 Close paralog for cross-reactivity specificity screening. |
View ERVV-2 Products |
| Related Target B | ERVK (HERV-K, HML-2) Most studied onco-retrovirus; benchmark for ERV family validation. |
View ERVK Products |
| Related Target C | ERVFRD-1 (Syncytin-2) Placental ERV control; assess tissue-specific off-target risk. |
View ERVFRD-1 Products |
| Related Target D | HERV-W (Syncytin-1) Specificity cross-screening control for placental function. |
View HERV-W Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Cross-species HERV family specificity (ERVV-1 vs ERVV-2 vs ERVK) | Ortholog Protein Panel available: Human ERVV-1, ERVV-2, and ERVK ECD-Fc proteins strictly verified by mass spec for off-target screening. |
| Native conformation preservation (Type I membrane protein) | Lentivirus particles for stable cell line generation; maintains native membrane topology and glycosylation for flow cytometry/immunofluorescence. |
| Lack of clinical reference standards | Research-grade benchmark antibody and sequence-verified siRNA controls included for assay standardization. |
| Endotoxin sensitivity in primary T-cell assays | Endotoxin controlled (<1 EU/ug); suitable for sensitive immunological applications. |
| Glycosylation-dependent epitope presentation | HEK293 Expressed (Native Glycosylation) to ensure proper structural folding. |
Live ERVV-1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
- ➤ View Active Clinical Trials
- ➤ Latest Immunotherapy Research
- ➤ HERV-V Expression Studies
- ➤ Recent Patent Filings
- ➤ Latest Resistance Research
Global Clinical Landscape & Future Outlook
The ERVV-1 target represents a frontier in tumor-associated antigen (TAA) discovery. As a reactivated endogenous retrovirus envelope protein expressed in testicular germ cell tumors (TGCT) and ovarian malignancies, ERVV-1 offers a unique "self" antigen that is selectively demethylated in cancer. Because normal tissue expression is largely restricted to the placenta, ERVV-1 provides an attractive therapeutic window. The current R&D landscape is transitioning from exploratory expression profiling to structured immunotherapy development, with TCR-T cell therapies and antibody-based modalities entering preclinical optimization. Major players are shifting focus from traditional mAbs to Antibody-Drug Conjugates (ADCs) and T-cell engagers. The next wave of development focuses on specificity engineering to distinguish ERVV-1 from phylogenetically related HERV family members, and combination strategies with immune checkpoint inhibitors to overcome the tumor microenvironment.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| TCR-T Cell Therapy | Academic Medical Centers, Early Biotech | Testicular Germ Cell Tumors (TGCT) | Peptide-MHC binding validation; Lentivirus for target cell engineering. |
| Monoclonal Antibody | Preclinical Discovery Labs | Ovarian Cancer | High-purity ECD-Fc for SPR/binding; Cross-reactivity panel (ERVV-2/ERVK). |
| Bispecific Engager | Emerging Biotech | Solid Tumors | Cell-based assays using Lentivirus-stable lines; Endotoxin-controlled proteins. |
| mRNA Vaccine | Academic Research | Cancer Vaccination | Sequence-verified ORF clones; Immunogenicity screening tools. |
| ADC | Early-stage Biotech | Solid Tumors (Ovarian, Breast) | Internalization Assay (Need high-purity ECD-Fc) |
| CAR-T | Academic Spin-offs | Advanced Solid Tumors | Selectivity Assay (Need Homolog Panel Proteins) |
Molecular Differentiation & Assay Strategy
1. Specificity & Safety
Challenge: ERVV-1 shares conserved epitopes with ERVV-2, ERVK, HERV-W, and ERVFRD-1. Therapeutic antibodies must precisely distinguish these to avoid off-target effects. Assay Strategy: Cross-reactivity panel screening using SPR or ELISA. TarMart Solution: Ortholog Protein Panel (Human ERVV-1, ERVV-2, ERVK, HERV-W, ERVFRD-1) with mass spec verification.
2. Conformational Integrity
Challenge: Env protein native conformation is critical for neutralizing activity; recombinant expression may lead to misfolding. Assay Strategy: Cell surface display validation via flow cytometry using stable cell lines. TarMart Solution: High-titer Lentivirus Premade Particles (>10^8 TU/mL) for rapid stable cell line generation with native glycosylation.
3. Immunogenicity Control
Challenge: Endogenous protein may induce tolerance; vaccines or cell therapies need to break immune ignorance. Assay Strategy: T-cell activation assays (PBMC + DC co-culture) and cytokine release detection (IFN-γ ELISPOT). TarMart Solution: Endotoxin-controlled (<1 EU/ug) proteins and siRNA for specificity verification.
4. Cross-species Reactivity
Challenge: HERVs are human-specific; no direct orthologs in mice/rats for preclinical safety. Assay Strategy: Humanized mouse models and tissue cross-reactivity (TCR) studies. TarMart Solution: Lentivirus for transgenic mouse cell models; high-purity ECD protein for IHC controls.